Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry

Niels Klarskov; Amanda Darekar; David Scholfield; Laurence Whelan; Gunnar Lose

doi:10.1007/s00192-013-2269-6

Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry

Niels Klarskov, Amanda Darekar, David Scholfield, Laurence Whelan, Gunnar Lose

Institut for Klinisk Medicin

6 Citationer (Scopus)

Abstract

INTRODUCTION AND HYPOTHESIS: The aim was to evaluate, using urethral pressure reflectometry (UPR), the effect of fesoterodine on urethral function in women with stress urinary incontinence (SUI).

METHODS: Women aged 18 to 65 years were eligible for this randomised, double-blind, placebo-controlled, crossover study if they had had clinically significant SUI or SUI-predominant mixed urinary incontinence for >3 months. Each participant received fesoterodine 4 mg, fesoterodine 8 mg, and placebo once daily for 7 days, with a 7- to 10-day washout between treatments. UPR was performed at baseline and 4 to 8 h after the last dose in each treatment period. Participants completed a 3-day bladder diary before randomisation and during the last 3 days of each treatment period.

RESULTS: Of the 22 women randomly assigned and treated, 17 met the criteria for the primary efficacy analyses. No statistically significant differences were seen between fesoterodine 4 mg or fesoterodine 8 mg and placebo in opening urethral pressure (primary endpoint) or other UPR endpoints. No statistically significant differences were seen between either fesoterodine dose and placebo in the change from baseline in the bladder diary variables (total urinary incontinence, SUI, or urgency urinary incontinence episodes per 24 h). Adverse events were reported by 8 participants taking fesoterodine 4 mg, 17 taking fesoterodine 8 mg, and 8 taking placebo.

CONCLUSIONS: Fesoterodine did not affect urethral pressure or significantly decrease the number of incontinence episodes in women with SUI. The UPR parameters showed no placebo effect, while there was a placebo effect of 60 % based on the bladder diary.

Originalsprog	Engelsk
Tidsskrift	International Urogynecology Journal
Vol/bind	25
Udgave nummer	6
Sider (fra-til)	755-760
Antal sider	6
ISSN	0937-3462
DOI	https://doi.org/10.1007/s00192-013-2269-6
Status	Udgivet - jun. 2014

Adgang til dokumentet

10.1007/s00192-013-2269-6

Citationsformater

@article{67aaf4866974414e9bf1f92a5b5a1651,

title = "Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry",

abstract = "INTRODUCTION AND HYPOTHESIS: The aim was to evaluate, using urethral pressure reflectometry (UPR), the effect of fesoterodine on urethral function in women with stress urinary incontinence (SUI).METHODS: Women aged 18 to 65 years were eligible for this randomised, double-blind, placebo-controlled, crossover study if they had had clinically significant SUI or SUI-predominant mixed urinary incontinence for >3 months. Each participant received fesoterodine 4 mg, fesoterodine 8 mg, and placebo once daily for 7 days, with a 7- to 10-day washout between treatments. UPR was performed at baseline and 4 to 8 h after the last dose in each treatment period. Participants completed a 3-day bladder diary before randomisation and during the last 3 days of each treatment period.RESULTS: Of the 22 women randomly assigned and treated, 17 met the criteria for the primary efficacy analyses. No statistically significant differences were seen between fesoterodine 4 mg or fesoterodine 8 mg and placebo in opening urethral pressure (primary endpoint) or other UPR endpoints. No statistically significant differences were seen between either fesoterodine dose and placebo in the change from baseline in the bladder diary variables (total urinary incontinence, SUI, or urgency urinary incontinence episodes per 24 h). Adverse events were reported by 8 participants taking fesoterodine 4 mg, 17 taking fesoterodine 8 mg, and 8 taking placebo.CONCLUSIONS: Fesoterodine did not affect urethral pressure or significantly decrease the number of incontinence episodes in women with SUI. The UPR parameters showed no placebo effect, while there was a placebo effect of 60 % based on the bladder diary.",

keywords = "Benzhydryl Compounds, Cross-Over Studies, Diagnostic Techniques, Urological, Double-Blind Method, Equipment Design, Female, Humans, Middle Aged, Muscarinic Antagonists, Pressure, Urethra, Urinary Incontinence, Stress",

author = "Niels Klarskov and Amanda Darekar and David Scholfield and Laurence Whelan and Gunnar Lose",

year = "2014",

month = jun,

doi = "10.1007/s00192-013-2269-6",

language = "English",

volume = "25",

pages = "755--760",

journal = "International Urogynecology Journal",

issn = "0937-3462",

publisher = "Springer",

number = "6",

}

TY - JOUR

T1 - Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry

AU - Klarskov, Niels

AU - Darekar, Amanda

AU - Scholfield, David

AU - Whelan, Laurence

AU - Lose, Gunnar

PY - 2014/6

Y1 - 2014/6

N2 - INTRODUCTION AND HYPOTHESIS: The aim was to evaluate, using urethral pressure reflectometry (UPR), the effect of fesoterodine on urethral function in women with stress urinary incontinence (SUI).METHODS: Women aged 18 to 65 years were eligible for this randomised, double-blind, placebo-controlled, crossover study if they had had clinically significant SUI or SUI-predominant mixed urinary incontinence for >3 months. Each participant received fesoterodine 4 mg, fesoterodine 8 mg, and placebo once daily for 7 days, with a 7- to 10-day washout between treatments. UPR was performed at baseline and 4 to 8 h after the last dose in each treatment period. Participants completed a 3-day bladder diary before randomisation and during the last 3 days of each treatment period.RESULTS: Of the 22 women randomly assigned and treated, 17 met the criteria for the primary efficacy analyses. No statistically significant differences were seen between fesoterodine 4 mg or fesoterodine 8 mg and placebo in opening urethral pressure (primary endpoint) or other UPR endpoints. No statistically significant differences were seen between either fesoterodine dose and placebo in the change from baseline in the bladder diary variables (total urinary incontinence, SUI, or urgency urinary incontinence episodes per 24 h). Adverse events were reported by 8 participants taking fesoterodine 4 mg, 17 taking fesoterodine 8 mg, and 8 taking placebo.CONCLUSIONS: Fesoterodine did not affect urethral pressure or significantly decrease the number of incontinence episodes in women with SUI. The UPR parameters showed no placebo effect, while there was a placebo effect of 60 % based on the bladder diary.

AB - INTRODUCTION AND HYPOTHESIS: The aim was to evaluate, using urethral pressure reflectometry (UPR), the effect of fesoterodine on urethral function in women with stress urinary incontinence (SUI).METHODS: Women aged 18 to 65 years were eligible for this randomised, double-blind, placebo-controlled, crossover study if they had had clinically significant SUI or SUI-predominant mixed urinary incontinence for >3 months. Each participant received fesoterodine 4 mg, fesoterodine 8 mg, and placebo once daily for 7 days, with a 7- to 10-day washout between treatments. UPR was performed at baseline and 4 to 8 h after the last dose in each treatment period. Participants completed a 3-day bladder diary before randomisation and during the last 3 days of each treatment period.RESULTS: Of the 22 women randomly assigned and treated, 17 met the criteria for the primary efficacy analyses. No statistically significant differences were seen between fesoterodine 4 mg or fesoterodine 8 mg and placebo in opening urethral pressure (primary endpoint) or other UPR endpoints. No statistically significant differences were seen between either fesoterodine dose and placebo in the change from baseline in the bladder diary variables (total urinary incontinence, SUI, or urgency urinary incontinence episodes per 24 h). Adverse events were reported by 8 participants taking fesoterodine 4 mg, 17 taking fesoterodine 8 mg, and 8 taking placebo.CONCLUSIONS: Fesoterodine did not affect urethral pressure or significantly decrease the number of incontinence episodes in women with SUI. The UPR parameters showed no placebo effect, while there was a placebo effect of 60 % based on the bladder diary.

KW - Benzhydryl Compounds

KW - Cross-Over Studies

KW - Diagnostic Techniques, Urological

KW - Double-Blind Method

KW - Equipment Design

KW - Female

KW - Humans

KW - Middle Aged

KW - Muscarinic Antagonists

KW - Pressure

KW - Urethra

KW - Urinary Incontinence, Stress

U2 - 10.1007/s00192-013-2269-6

DO - 10.1007/s00192-013-2269-6

M3 - Journal article

C2 - 24258099

SN - 0937-3462

VL - 25

SP - 755

EP - 760

JO - International Urogynecology Journal

JF - International Urogynecology Journal

IS - 6

ER -

Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater